News

Categories

July 28, 2025

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

July 17, 2025

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

July 10, 2025

Zymeworks Wins Life Sciences BC 2025 Company of the Year Award

May 30, 2025

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

May 22, 2025

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

May 21, 2025

Zymeworks Announces Participation in Upcoming Investor Conferences

May 19, 2025

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

May 8, 2025

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

April 25, 2025

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

April 21, 2025

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

April 17, 2025

Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

April 10, 2025

Zymeworks to Present at the AACR Oncology Industry Partnering Event